Upadacitinib
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
- Upadacitinib
- Upadacitinib: From Unspecified Original Indication to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
Upadacitinib: From Unspecified Original Indication to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
One-Sentence Summary
The original indication and mechanism of action (MOA) for Upadacitinib are not available in this evidence pack (data gap). The TxGNN model predicts potential effectiveness for Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome, but currently 0 clinical trials and 0 publications support this direction — the prediction rests solely on the model score.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (data gap — no original_indications recorded) |
| Predicted New Indication | Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome |
| TxGNN Prediction Score | 99.61% (rank 3815) |
| Evidence Level | L5 |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Upadacitinib is not currently available in this evidence pack, and no original indication has been recorded, so the pharmacological link between the drug and the predicted new indication cannot be established from the source data provided.
The predicted indication — colobomatous microphthalmia-rhizomelic dysplasia syndrome — is a congenital ocular/skeletal developmental disorder. Based on the supplied rationale, there is no known association between JAK/STAT or inflammatory pathways (the pathway class Upadacitinib is generally known to act on) and the pathophysiology of this structural developmental syndrome. No preclinical or clinical literature currently supports a mechanistic hypothesis for this pairing.
Given the absence of MOA data, original indication data, and any supporting trials or literature, this prediction should be treated as a pure model output (TxGNN score 0.9961) rather than a mechanistically or clinically substantiated repurposing candidate.
Note: A second candidate indication, brachydactyly-syndactyly syndrome (score 99.58%, rank 4049), was also predicted with the same lack of supporting mechanistic, trial, or literature evidence, and carries the same Hold recommendation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
New Zealand Market Information
Upadacitinib is currently not marketed in New Zealand, and no authorization records exist (0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information.
(All key warnings, contraindications, and drug interaction data are marked as data gaps in this evidence pack; the TFDA package insert warnings/contraindications item is flagged as a blocking data gap preventing S1 safety pre-assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale: No mechanism-of-action data, no original indication record, and zero clinical trials or literature support this prediction — it is based solely on an unvalidated TxGNN model score (L5), with a blocking safety data gap outstanding.
To proceed, the following is needed:
- TFDA/regulatory package insert (warnings, contraindications) — currently blocking
- Confirmed original indication(s) and mechanism of action (MOA) for Upadacitinib
- Drug interaction (DDI) data
- Mechanistic plausibility review linking JAK-inhibition pathways (if confirmed as MOA) to the predicted congenital developmental syndrome
- Any preclinical, case-report, or trial evidence for this specific indication pairing before advancing beyond S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.